Ionis Q3 revenue $157M, up 17% YoY; raises FY 2025 guidance on TRYNGOLZA strength

IONIS PHARMACEUTICALS INC

2025-Q3 EPS reported -$0.95 revenue$740,381,000

TRYNGOLZA Q3 net sales $32M, ~70% QoQ increase; FY guidance raised to $85-95M.
Olezarsen Phase 3 sHTG: 72% TG reduction, 85% AP reduction; sNDA by year-end 2025.
Zilganersen positive pivotal in Alexander disease; NDA submission planned Q1 2026.
Total revenue guidance raised to $875-900M; non-GAAP op loss guided to $275-300M.
Cash and investments $2.2B as of Sep 30; DAWNZERA launched in August 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.